

ParkinSense: Contactless Parkinson's Disease Diagnosis, Telemonitoring, and Severity Analysis via Multimodal Machine Learning and Digital Biomarkers

Pulkith Paruchuri

Heritage High School

I. ABSTRACT

Despite being the fastest growing Neurodegenerative disease in the world, Parkinson's Disease (PD) currently has no definitive diagnosis. Current methods of diagnosis are inaccessible to billions due to geographic, economic, and age-related mobility barriers, disproportionately so in rural areas or regions without ready access to healthcare; PD diagnosis can cost upwards of \$5K, require a lengthy visit to a nearby neurologist, and can involve intensive scans. Notwithstanding, currently, almost 1 in 3 patients are misdiagnosed, and an estimated 40% of patients with PD are never successfully diagnosed with PD. Since treatment is often more effective in the earlier stages of PD, these issues are vital to remedy. ParkinSense, a web and mobile application, was developed to combat these issues. ParkinSense allows one to diagnose themselves for PD from anywhere in the world in under 12 minutes, requiring only a device and internet connection. ParkinSense analyzes 3 cardinal symptoms of PD entirely contactlessly and automatically: Dysarthria, Hypomimia, and Bradykinesia. It involves multiple machine learning models that utilize ensemble learning and multimodal data fusion to improve accuracy. ParkinSense boasts an overall accuracy rate of 99.72% when validated on public database points, synthetic patients, and 106 authentic patients. Even after proper diagnosis, there is a critical need to monitor PD severity, to analyze disorder progression and the effectiveness of certain treatments. ParkinSense is able to estimate the disease severity on the two common PD severity classification scales: the UPDRS, and the H&Y Scale, with a normalized root mean square error of less than 0.0907 on the UPDRS. Furthermore, trends of severity can be analyzed over time via a GUI. Not only is ParkinSense contactless, rapid, accurate, and cheap, it is the first public method of remote PD diagnosis and severity analysis, potentially providing billions with a crucial healthcare tool.

II. INTRODUCTION

Parkinson's Disease (PD) is the second most prevalent neurodegenerative disease in the world [1]. With Parkinson's Disease being the fastest-growing neurodegenerative disease globally [2], the number of cases has surged to over 10 million in the last few decades, and this figure is expected to at least double by 2030 [3]. Parkinson's Disease results from the death of dopaminergic neurons in the substantia nigra pars compacta [4]. This neurodegeneration affects largely those over the age of 40 [5] and leads to progressive disability [6]. Due to this progressive nature of PD, early and accurate diagnosis is vital for effective treatment, to stagnate or prevent further neuronic loss [7]-[9]. This neuronic loss affects both motor and non-motor skills [10]. Some of the hallmarks of the disorder include bradykinesia (slowed movement), speech irregularities, tremors, visual impairment, postural instability, rigid muscles, and more [11]. Traditional and industry-standard diagnostic approaches typically take the form of extensive questionnaires that involve the manual examination and measurement of certain behaviors [12]. However, these are highly subjective to the administering clinician, relying on the detection of characteristics and behavior that may be too minute to be reliably noticed by one's eyes [13]. While a few technologies, such as Magnetic Resonance Imaging (MRI) and DaTScan scans can aid in PD diagnosis, they can offer little information beyond differentiating Idiopathic Parkinsonism from atypical forms of Parkinsonism or other diseases [14]. As such, they can typically only be used to exclude other disorders. Not only do many neurological disorders, such as Essential Tremor [14], share symptoms with PD, but many parkinsonism symptoms arise naturally in PD-susceptible, but healthy, individuals, as a result of old age, complicating PD diagnosis [15]-[17]. Resultantly, nearly 1 in 4 patients are misdiagnosed during a PD diagnosis at least once [18], severely inhibiting the effectiveness of potential treatments, and enabling the disease time to progress [19]. Furthermore, such a diagnosis typically is conducted in a hospital or institution with trained clinicians [20]. Coupled together, these difficulties essentially render PD diagnosis inaccessible to many, specifically those mainly in developing regions, or those without access to affordable healthcare [21]. The goal of this study was to create an accurate, rapid, and accessible method of PD diagnosis and severity analysis.

III. RELATED WORKS

With technology significantly emerging into the healthcare industry over the past few decades, a great deal of literature has been published regarding PD diagnosis with the assistance of computational resources. Multiple approaches have been tried, including things such as Wearable Technology and MRI scans [22], [23]. However, a proven and accurate method of diagnosis has been elusive. A promising portion of this healthcare-technology convergence is Machine Learning. Machine Learning has been seen to be effective in signaling PD in an individual, by analyzing data such as vocal irregularities, MRI scans,

sebum RNA, and much more [24]- [26]. For the purpose of this study, a focus was placed on machine learning methods for PD diagnosis that can be conducted contactlessly (e.g. without wearable technology, or MRI scans).

While numerous symptoms are present in PD patients, three were chosen for this study, stemming from their ability to easily and accurately be assessed noninvasively, with minimal technical requirements, ensuring accessibility while retaining reliability.

3.1 Dysarthria

Dysarthria categorizes the vocal irregularities deriving from the hypokinetic nature of parkinsonism [27]. It can cause abnormalities and monotonicity in intonation, tone, volume, fluidity, and more [28].

Several studies have attempted to identify vocal irregularities via Machine Learning for PD diagnosis, and it was found that sustained vowel phonations, of /a/, for example, have proven to be effective in differentiating PD patients from Healthy Controls (HC) [29], [30].

3.2 Hypomimia

Also referred to as ‘Facial Masking’, Hypomimia is the reduction in pronunciation, and rapidness of facial expressions, arising from the rigidity many PD patients encounter in their facial muscles [31].

The human face can be partitioned into groups of Action Units (AU), that represent groups of facial muscles [32]. When making certain facial expressions, such as disgust or surprise, numerous AUs are activated, and the variance of the magnitudes of this activation quantifies the amount of muscle movement, which in turn, can divulge information about the presence of PD [33]. Reference [33] discovered that Hypomimia is a promising method for PD diagnosis.

3.3 Bradykinesia

Bradykinesia describes the slowness-of-movement characteristic of many PD patients, and Eye Blink Rate (EBR) can be used as a test for Bradykinesia [14].

Although no one in literature has used Machine Learning with EBR for PD diagnosis, numerous studies have shown statistically significant differences between the EBR of PD patients, and HC, providing a promising space to exploit for PD diagnosis [34]. During a reading task, it was found that PD individuals averaged only 2.4 blinks per minute, while HC averaged 10.7 blinks per minute [35].

3.4 Multimodal Diagnosis

While many classification algorithms with Machine Learning can perform quite well on PD diagnosis, they often rely on only one symptom, as can be seen in sections 3.1-3.3. While this can be effective, the onset and severity of many PD symptoms vary greatly as some symptoms may never manifest in a PD patient, while others typically only manifest noticeably in the middle to late stages of PD after 20 years [36], [37]. As such, it is unreliable to use only unimodal classifiers. Furthermore, past multimodal studies,

ParkinSense: Contactless Parkinson's Disease Diagnosis, Telemonitoring, and Severity Analysis via Multimodal Machine Learning and Digital Biomarkers

for not only PD diagnosis, but the diagnosis of other neurodegenerative diseases, have shown that multimodal models can offer significant performance improvements over unimodal classifiers [38], [39].

3.5 Severity Analysis

The Hoehn and Yahr Scale (H&Y Scale) is a 5-point scale [40], and the Unified Parkinson's Disease Rating Scale (UPDRS) is a 199-point scale [12], widely used for quantifying disease severity and progression. Both of these scores are conventionally calculated through lengthy questionnaires. that rates a PD patient's level of disability and disease progression, from the evaluation of dozens of tasks by a clinician. A few have managed to estimate disease severity on these scales from symptoms with Machine Learning effectively [41].

IV. DATA SOURCES

TABLE I PUBLIC DATASET SOURCES & DESCRIPTIONS

Dataset	Size	Feature s	Participants PD	Participant s HC	Mean Age	% Male	Content Utilized	H&Y Scale	UPDRS Score
A	240	46	40	40	N/A	60%	/a/ phonations	No	No
B	1040	26	20	20	64.9±9	60%	/a/, /o/, /u/ phonations, words, sentences	No	Yes
C	168	26	28	0	62.7±11	N/A	/a/, /o/ phonations	No	No
D	5875	26	42	0	65.4±9.24	67%	/a/ phonations	No	Yes
E	756	754	188	64	64.1±10.6	52%	/a/ phonations	No	No
F	1812	12	61	543	63.9±7.8	38%	AU Variances	No	No
G	61	10	20	41	70.7±9.1	41%	Reading EBR	Yes	No

ParkinSense: Contactless Parkinson's Disease Diagnosis, Telemonitoring, and Severity Analysis via Multimodal Machine Learning and Digital Biomarkers

Data was gathered from a variety of sources. All data was gathered or collected from sources that obtained data in scientifically rigorous environments and methods. An outline of public data sources, content, sizes, and other information can be found in Table 1. Along with the information explicitly stated in Table 1, most datasets also contain demographic information (but no identifying information) regarding the participants, such as age, gender, and how long they've had PD for those who tested positive for PD.

4.1 Dysarthria

Datasets A-E of Table 1 describes the data collected for the Vocal Analysis Modality [42]-[46]. These datasets contain information on various vocal features, such as fundamental frequency, variations in this frequency (absolute shimmer), and the ratio of noise to tonal components. These features are collected as the user vocalizes sustained vowel phonations, typically for 10 seconds. Certain datasets were aggregated together, the first time this has been attempted in literature for Parkinson's Disease diagnosis. The features used for most vowel phonations represent the intersection of the features in the datasets for that specific phonation.

4.2 Hypomania

Facial Expression Data was collected from the study in [33]. This data is shown as Dataset F in Table 1, and contains information regarding the variance of the magnitude of the corresponding Action Unit involved with Smile, Surprise, and Disgust facial expressions, during activated phases.

4.3 Bradykinesia

Eye Blink Rate Data, sourced from [35] is represented in Dataset G of Table 1 and provides information about the Eye Blink Rate of participants during a reading task, a conversation task, and a television-watching task. For the purpose of the study, only data from the reading task was utilized. Half Blinks, a phenomenon in many PD patients, where the eye may twitch and cause a blink that only partially obscures the eye, were also collected. It was noted whether or not the patients wore glasses.

4.4 Authentic Patients

An online data-collection platform, was developed to collect data from authentic patients, without requiring the patients to commute to a facility or clinic for data extraction. This also allows a mimic of how data will be collected and analyzed with the diagnosis site. 124 Healthy Controls (including individuals who were diagnosed with other neurodegenerative diseases, but not PD), and PD patients were recruited online. Data was collected as they completed the process as outlined in section 5.2, and their PD diagnosis was recorded, as with their age, gender, H&Y rating score, and UPDRS score as applicable. Care was taken to preserve the anonymity and privacy of the patients. The only information that was collected that could be used to identify the patient was data collected from the videos and audio clips submitted by the patient (but no name, address, email, etc... was collected). However, after the data was automatically featurized and irreversibly converted to a numerical format, all the identifying data (facial expressions, vowel phonations,

ParkinSense: Contactless Parkinson's Disease Diagnosis, Telemonitoring, and Severity Analysis via Multimodal Machine Learning and Digital Biomarkers

etc...), was automatically discarded. No individual worked with the identifying data in order for it to be featurized was the researcher itself, and as a result, no other individual was in contact with the identifying information.

No diagnosis, results, or advice was provided to the patient after they completed their study. They provided their data with no compensation. Section 5.1 provides more information.

As such, data was collected in a manner that abides by all HIPPA Privacy regulations, OSHA regulations, and local regulations. An informed consent form must be completed by all users before they use the application to provide data or get diagnosed. Users can withdraw their data from the study at any time and have their data removed from the study.

4.5 Severity Analysis

A few of the datasets contained information regarding the severity of PD patients, which is used for the severity profiling stage of ParkinSense. The specific datasets which contain such information can be found in Table 1. Datasets either contained the severity on the UPDRS or the H&Y scale.

V. METHODOLOGIES




Fig. 1. Web application overview, data processing methods, and feature extraction technologies as described in sections 5.2-5.4.

5.1 Website and Application Overview

Two websites and a mobile app are developed in this study. The Data Collection Site (DCS) labels the website that was used to collect data from authentic patients. It returned no information to the participant. The Diagnosis & Severity Analysis Site (DSAS), and mobile app were developed as the product of the study, allowing individuals to diagnose themselves for PD, and if a positive diagnosis is returned, classify their severity. Both websites are nearly identical in the layout and process, so features that allow for ease of use in the DCS site can be translated over to allow for similar ease of use in the DSAS site. Patients enrolled in this study only accessed the DCS to provide their data. No users accessed the DSAS or mobile

application except for the researcher, and thus, no patient was informed of their diagnosis, severity, or any other medical information as calculated by the application.

5.2 Data Collection Site

A diagram of the DCS site, which is to be further described in this section, can be found in Fig. 1.

When users navigate to the web application and begin the diagnosis, they are first asked to be in a seated position, with their laptop or computer one foot away from them, such that their entire head and part of their torso are in the frame, not dissimilar from a passport photo. They are requested to complete the study at a time when they are well-hydrated and not tired. Finally, they should be in a quiet location, with their face well-lit.

Before they begin the diagnosis, they are prompted with a screen that allows them to adjust their camera and microphone volume, so they are able to be in the optimal position relative to the above conditions when they begin the diagnosis.

1) *Vocal Analysis:* When users begin the diagnosis through the web application, they are first asked to vocalize sustained vowel phonations, for as long as they can, or until 10 seconds elapse, whichever is shorter. It was emphasized that they should maintain constant volume and pitch. They are requested to complete three such phonations: /a/, /u/, and /o/

2) *Facial Expressions:* Then the user is asked to make 3 pronounced facial expressions: joy, surprise, and disgust. To improve accuracy users were asked to make each face three times in succession, alternating with a neutral face.

3) *Short Passage:* In this section, users were asked to read as much as they could of a selection of 5 passages for 60 seconds. They were asked to read at their regular reading speed, volume, and voice. The specific reading passages were chosen for having a diverse set of words and containing phrases that might divulge important information for the diagnosis. Paragraphs were ordered in order of expected relative importance, since users may not have time to read all five paragraphs in the allotted time with their regular reading speed. From this section, data was gathered for vocal analysis, to be split up into small sentences, phrases, and individual words, and video data was collected for EBR analysis.

4) *Questionnaire:* The final section of the diagnosis involved a short questionnaire, asking a few questions including gender, age, and whether the individual wore glasses during part 3 (Short Passage).

5.3 Preprocessing

Data processing and Feature Extraction was done entirely through an automated pipeline, to mimic the requirements for automated data processing when used as a web application for rapid diagnosis. Certain requirements, such as a decibel ceiling and floor were enacted to prevent data from which it was difficult to extract features accurately to transform into a form of adversarial data that could lead to an incorrect

diagnosis. This step of preprocessing led to the loss of some participants from the authentic dataset, reducing the functional size of the dataset from 124 to 106.

1) *Vocal Analysis:* First vocal data was separated from webcam data, and webcam data was discarded. Additionally, the recording was trimmed, such that the first 0.5 seconds of the recording were discarded, since the onset of speech results in nonuniform levels of pitch and volume. Additionally, the last 2 seconds were thrown out, since, during this timeframe, the user typically runs out of breath, resulting in diminishing volume and degrading pitch that does not represent the user’s true vocalization.

2) *Facial Expressions:* Each participant submits 3 videos, each containing 6 facial expressions (3 of the requested facial expression, and 3 neutral faces), for a total of 18 facial expressions(9 total facial expressions for smile, surprise, and disgust). For facial data, each of the 18 facial expressions was run through DeepFace [49] to ensure the correct facial expression was made. If the incorrect facial expression was detected, the recording was discarded.

3) *Short Passage:* For data derived from the reading passage, vocal and webcam data were split from each other. Vocal data was split up into individual words using the Pydub module [51], which was temporally paired with the words in the passage, to create a mapped transcript.

4) *Data Augmentation:* Because of the relatively smaller size of the EBR dataset, even relative to the unaggregated datasets of the Vocal Modality, Data Augmentation techniques were used to augment the size of the dataset. In this case, because the HC class was quite larger than the PD class, the Synthetic Minority Oversampling Technique (SMOTE) was used to generate new examples for the PD class.

5.4 Feature Extraction

1) *Vocal Analysis:* Features were extracted from vocal data that represents the intersection of Features in datasets A-E. These features were extracted using openSMILE 3.0 [48].

2) *Facial Expressions:* With a server-hosted instance of OpenFace 2.0 [50], the magnitude of the AUs associated with each of the 3 requested facial expressions was calculated when the expression was being made, and the variance of these AU magnitudes was calculated, representing the amount of facial movement. Recordings were split at the midpoint troughs of AU non-activation, indicating a neutral face.

3) *Eye Blink Rate:* Because of the need to measure half-blanks in the study, no suitable pre-developed was found that was able to calculate the measurements needed for this study [52]. A solution was built instead to count these numbers of eye blinks.

First, I landmark the face to localize important regions of the face, and to derive 6 points around the perimeter of the eye. p_1 and p_4 are on the left and right corners of the eye, p_3 , p_2 , p_6 , and p_5 are along the center of the circumference of the eye in Quadrants 1, 2, 3, and 4 respectively. Then in this landmarked region, a small number of points are sampled to determine the Eye-Aspect-Ratio (EAR), determining a ratio of the eye height to eye width as calculated by:

$$EAR = \frac{\|p_2 - p_6\| + \|p_3 - p_5\|}{2\|p_1 - p_4\|}$$

For this study, an EAR equal to or below 0.20 was counted as a full blink, and an EAR below 0.30 was determined to be a half-blink.

However, it was found that EAR was unreliable when detecting full blinks due to varying eye sizes. As a result, another metric was defined, the Eye Coverage Ratio (ECR), which calculates the amount of eye, bounded by the 6 landmarked points, that is covered by the eyelid. An ECR above 0.9 coupled with an EAR below 0.2 was counted as a full blink.

To calculate this ECR on the eye region, a few approaches were attempted. Simple Monte Carlo Estimation, where a large number of random points are sampled, and the estimation of the ECR can be calculated. However, since the ECR had to be calculated for dozens of frames a second, this was deemed unfeasible. Then a predetermined sample of points was to be used, but due to the depth and non-spherical shape of the eye, it was difficult to determine a uniform sampling. As a result, points were generated with the constraint that they are well-spaced and roughly uniform. To accomplish this, the eye was generalized as a 2-dimensional horizontal plane. Then a maximin construction was attempted, which sequentially generates points to maximize the distance of a point from all its neighbors. However, this approach was found to generate a proportionally surplus number of points on the perimeter of the eye and was thus abandoned. In its place, Reisz S-energy, a generalization of potential energy was used. In this, the potential between two points z^i and z^j is defined as

$$U(\mathbf{z}^{(i)}, \mathbf{z}^{(j)}) = \frac{1}{\|\mathbf{z}^{(i)} - \mathbf{z}^{(j)}\|^s}$$

I aim to minimize U_T , the overall s -energy. I take the logarithm of U_T , and compute the partial derivative $F_E = \log(U_T)$ with respect to $z_m^{(i)}$ as shown below:

$$\frac{\partial F_E}{\partial z_m^{(i)}} = -\frac{d}{U_T} \left[\sum_{\substack{j=1, \\ j \neq i}}^n \frac{(z_m^{(i)} - z_m^{(j)})}{\|\mathbf{z}^{(i)} - \mathbf{z}^{(j)}\|^{s+2}} \right]$$

Adam gradient-based optimization was performed for 3,000 iterations to generate a sample of well-spaced points to calculate the ECR rapidly. This approach proved to be successful both with and without glasses.

5.5 Model Framework

A diagram of ParkinSense's Diagnosis Model Framework can be seen in Fig. 2. ParkinSense's diagnosis framework revolves around the use of multiple classifiers to provide a binary classification of PD presence in a subject.




Fig. 2. Data sources, aggregation categories, preprocessing, and the model pipeline. The pipeline includes the diagnosis model, severity analysis model, and validation on synthetic patients. w represents the weights of certain estimators when used in voting classifiers and regressors. Severity is only evaluated following a positive diagnosis.

1) *Dysarthria*: Given the ample literature on Vocal-based methods of PD diagnosis, numerous classifiers and models have been well-tested and documented. In this step, the feature set was reduced to 10 using Genetic Algorithm-based feature set selection for all datasets. A Support Vector Machine (SVM) and Random Forest were used via Ensemble Learning with a Logistic Regression combination classifier to provide a single binary classification for /a/. For /o/ and /u/, an Adaboost Classifier and Gradient Boosted Classifier were used respectively, as they provided the best performance out of the tested classifiers. Finally, a random forest was used for both words and short-sentence classification. A final binary classification for Dysarthria-based methods was generated through hard majority-voting decision fusion, from the 5 individual classifiers. Weighting individual classification during the decision fusion stage did not seem to outperform equal weighting in this study.

2) *Hypomimia*: Three sets of 3 facial expressions were recorded for each user. A Support Vector Machine with a Radial Basis Function Kernel was used on each set and combined with a majority voting decision fusion to generate a single binary classification for this modality.

3) *Bradykinesia*: For EBR, a Supervised Multi-layer Perceptron was used to predict a binary classification.

4) *Modality Decision Fusion:* To combine the decisions from each modality, Soft Voting was used, with weights of 0.30, 0.35, and 0.35 used for Dysarthria, Hypomimia, and Bradykinesia respectively. In the case of the public model, if the confidence of the algorithm was low, the application did not return a diagnosis to prevent a misdiagnosis. However, for the purpose of the study, the diagnosis was always returned irrespective of the diagnosis confidence.

5) *Severity Analysis:* In the case of a positive diagnosis, ParkinSense predicted two scores: H&Y and UPDRS. H&Y Score was predicted via Stochastic Gradient Descent Regression using EBR data. UPDRS scores were predicted from datasets B and D individually, using Gradient Boosted Tree Regressors, and used a voting regressor, with 80% weight assigned to dataset B, due to its larger size.

6) *Iteration:* Bayesian optimization was used to tune the hyperparameters.

7) *Evaluation:* Due to the difficulty in finding data, especially on all modalities simultaneously, high-fidelity synthetic patients were generated as described in section 5.8. Authentic Patients were also used. K-fold cross-validation was used for all model evaluations, coupled with metrics discussed in section 6.

5.6 DSAS and Website Deployment

The DSAS closely mimicked the DCS but provided the diagnosis and severity as well.

The diagnosis website was developed with React.js and deployed on a personal domain with a signed certificate. Data is collected client-side and processed server-side. The unprocessed video and audio data was stored server-side, then discarded after being processed to protect user privacy. The

Server-side was written in (PHP), and connected to the front-end through (AJAX) requests. The trained models were created in Python via Scikit-Learn, hosted in Amazon Web Services (AWS), and accessed by the server through an AWS Gateway API.

5.7 Mobile Application

A mobile application was also developed, that was built so that users could track the severity over time easily, and share their information with other users. This was also done, because a mobile application allows for the collection of tremor data from the user, through the phone’s built-in accelerometer. This could be quite informative for a diagnosis because tremors are the hallmark of Parkinson’s Disease. However, the tremor collection was later excluded for now, because the calibration of the accelerator was difficult to accomplish, and the values calculated from the accelerator between phones under the same environment, as well as between a phone and a study in literature were found to be quite different. This would result in an inaccurate diagnosis.

However, the mobile application was still developed. The mobile application was similar to the website, in that it allowed the user to complete a diagnosis. However, it had some extra information including the ability to share data with a neurologist in real-time, and the ability to share data with friends

ParkinSense: Contactless Parkinson's Disease Diagnosis, Telemonitoring, and Severity Analysis via Multimodal Machine Learning and Digital Biomarkers

and family for monitoring. Users could also log and track treatments and medications, which allowed them to calculate disease severity and progression changes as the result of a specific treatment or medication. This could prove to be vital for PD treatment in the future, because some treatments or medications may not be effective in a patient, or may even adversely affect a patient. This would be paramount in monitoring the use of disease progression, and in monitoring the effectiveness of certain medications, and this is the first application of its kind.

The app also informed the user of important news and updates, including up-and-coming medications or treatments. It also notified the user when they did not update their severity or get diagnosed in a few weeks. The cross-platform app was built using SwiftUI and Flutter, and was built upon CardinalKit to ensure data privacy.

5.8 Synthetic Patients

To test the effectiveness of the multimodal model, over the unimodal classifiers, data had to represent individuals with data for all modalities. However, no such data exists due to this study's novelty. As a result, new data had to be collected or synthetic data had to be generated. In this study, both of these were entertained.

Synthetic Patients have been shown to mimic Authentic Patients quite closely and provide near-identical results [53] Synthetic data was generated by using variational autoencoders. These autoencoders generated patients which were similar, but slightly different from the original modality dataset. From this, full patients were generated across modalities, by matching data instances from each modality that were most similar in demographics.

Gender and PD diagnosis were strict matching criteria, meaning that a data instance from one modality had to equal the gender and PD diagnosis of the paired data instance from another modality. The other metrics, such as severity, age, and years since diagnosis, were loose criteria and were matched with, propensity score matching. In the end, this process generated high-fidelity synthetic patients.

5.9 Authentic Patients Offline Batch Retraining

As described previously, authentic patients were utilized to collect ground truth data that was not generated. Offline batch retraining was attempted. In one trial, after every 5 iterations of the diagnosis on the authentic patients, the individual dataset modalities will be augmented with the true results of the authentic patients that have been diagnosed so far, and the model will be retrained.

This is how the researchers plan the final website product to work as well. After a successful diagnosis, the participant can choose to get a diagnosis from their neurologist and can submit this official diagnosis to ParkinSense. After a specific number of these official diagnoses have been submitted, the model will be retrained with the new data, allowing for an increase in accuracy over time. However, the model will only

be retrained on data where ParkinSense and the official diagnosis do not differ, as in cases where they do differ, it cannot be deduced whether the misdiagnosis was from the official diagnosis or from ParkinSense.

VI. RESULTS & DISCUSSION

In most cases, synthetic data, and authentic data resulted in quite similar metrics, despite their sizable difference in the number of instances. As a result, the metrics reported in sections 6.1 and 6.2 represent the aggregation of both the synthetic and authentic data to present a more accurate representation of the model.

6.1 Model Diagnosis

Accuracy (a), precision (p), recall(r), F-1 score (f), specificity (s), and negative predictive value (n) scores were used as the metrics for this task.

TABLE II CLASSIFICATION EVALUATION METRICS

Model	a	p	r	s	f	n
Vocal Modality	0.963	0.947	0.985	0.939	0.966	0.982
Facial Modality	0.958	0.909	0.976	0.941	.941	0.987
EBR Modality	0.860	0.714	0.938	0.824	0.811	0.966
Overall Model	0.997	0.994	0.999	0.996	0.997	0.999

TABLE III SEVERITY EVALUATION METRICS

Model	NRMSE
Overall H&Y Prediction	0.0430
Dataset B UPDRS Prediction	0.2280
Dataset D UPDRS Prediction	0.1123
Overall UPDRS Prediction	0.0907

The diagnosis model results for each modality, and the overall model, can be seen in Table 2. At large, all modalities had accuracy rates above 86%, with vocal analysis being the most accurate, and EBR being the least accurate, although still quite accurate.

The high value of r is important, as it is vital to reduce false negatives as much as possible in the medical diagnosis industry. Additionally, the high value of r is a testament to the accuracy of ParkinSense, since the HC class was quite larger than the PD class, yet ParkinSense was able to achieve both a high a and a high r simultaneously. This was the first time EBR was calculated for diagnosis and severity analysis via Machine Learning algorithms. Although EBR was the least accurate in terms of accuracy compared to the other modalities, this provides promising evidence of its use for diagnosis. It is likely this accuracy can be increased if other features are also analyzed, such as blink latency and the time between blinks. Additionally, features were ranked according to their predictive value (i.e. a feature with a higher predictive value is more vital for an accurate diagnosis). Seen in Fig. 4, are some of the features that had the greatest predictive value for both a positive and negative diagnosis, out of all the features utilized.

6.2 Severity Analysis & Telemonitoring

The performance of the severity regression models was assessed via normalized root mean square error (NRMSE), with the scale range as the divisor. Results can be found in Table 3. Overall, ParkinSense's severity analysis model can be used to quite accurately predict both UPDRS and H&Y rating scale scores




Fig. 3 Augmentation Effectiveness for the EBR modality. Augmentation effectiveness plateaus after the dataset contains around 280 instances.




Fig. 4 Relative Predictive Power of select features from the overall model. Green indicates positive predictive power, while blue indicates negative predictive power.

with quite a significant accuracy. This allows users to monitor disease progression and medication effectiveness over time. Although an analysis of the effectiveness of this telemonitoring feature could not be evaluated as no longitudinal observation studies were conducted for a few years, it can be reasonably inferred they would be quite practical. Furthermore, users can submit their past and current severity scales to a neurologist for expert analysis or for benchmark comparison.

6.3 Comparative Analysis

1) Past Models: ParkinSense's individual classifiers outperform the vast majority of unimodal diagnosis models, in literature [54], especially the vocal modality, likely owing to the dataset aggregation, synthetic patient generation, and use with authentic patients. ParkinSense as a whole outperforms all unimodal models when tested on datasets larger than 25, all multimodal models, and even models that use invasive or nonremote data, such as MRI scans and extracted DNA sequences [54]. Additionally, ParkinSense outperforms the vast majority of models for severity analysis on both the UPDRS and H&Y severity prediction, although this phenomenon is much more apparent with the UPDRS. Additionally, if I limit analysis to models that only utilize data that can be collected remotely and noninvasively, ParkinSense provides massive improvements over current prediction models for UPDRS estimation. Overall, ParkinSense outperforms the average diagnosis classifier by 29% (in terms of accuracy), and the average severity classifier by 124% .

2) Authentic vs Synthetic This was one of the first instances of analysis of the difference between Synthetic and Authentic Patients, especially in the Parkinson’s Disease field. a , r , and, f , were compared between synthetic and authentic patients. Fig. 5 shows the trends of a , r , and, f , as the models were retrained with different proportions of the initial training set. As seen, typically, the trends closely relate to each




Fig. 5 Accuracy, recall, and f-1 score of synthetic vs authentic patients.

other, especially when the training set covers a few hundred instances. Scores for both the synthetic patients and authentic patients converge to a similar value. This is despite the fact many of the synthetic patients were composed of data that was derived from a laboratory or clinical setting, with a more sensitive microphone, cameras, and other equipment, than that of the laptops used by authentic patients. This further provides evidence that helps validate high-fidelity synthetic patients as a viable option to mimic authentic patients.

3) Augmentation Effectiveness This was the first time data was augmented before use in the Parkinson’s Disease Field. Augmenting data via SMOTE proved to be effective. In this study, EBR data was augmented from under 100 instances, to over 300. Fig 3 shows the trend of accuracy after the augmentation of the EBR diagnosis classifier, for various amounts of augmented data. In this case, the accuracy does plateau after around 86%, indicating that there are still specific characteristics or peculiarities that are not discernable after using Machine Learning algorithms on a small dataset, even after augmenting.

4) ECR Calculation Points For the ECR calculation, the set of data points was generated via both Maximim, and Riesz-S Energy. As seen in Fig. 6, maximum distributions had nonuniform marginal distributions, which could prevent accurate ECR calculation. This can be explained, as Maximin often pushes points toward the edges, especially in cases where a small number of points are generated. However, as seen in Fig. 7, Resiz-S energy generated a quite uniform set of points across all dimensions.

5) Aggregation Effectiveness This was the first instance of aggregating multiple datasets for a single diagnosis of Parkinson's Disease during preprocessing (i.e. not via Ensemble Learning or other similar methods). Aggregating the datasets significantly outperformed using individual datasets for vocal analysis, with the aggregated dataset model outperforming the single dataset models by 19.6% on average.




Fig. 6 Marginal Distributions after Maximin generation and after Resiz-S Energy. Riesz-S Energy is much more uniform and well-spaced on both axes.




Fig. 7 Reciever Operating Characeritic Graphs for multiple stages of PD and for Healthy Controls.

6) Stage-Specific Assessment Finally, the Receiver Operating Characteristics were compared at various stages: healthy, early, and mid-advanced, after training on only a portion of the training set, so that changes could be apparent. As seen in Fig. 7, the diagnosis best differentiates the mid-advanced stage PD from HC, compared to other stages, which is expected, since more symptoms are present in the later stages, and the symptoms typically are more prominent. However, even with the early-stage diagnosis, and the healthy patient diagnosis, the application was successful in diagnosing true positives without incurring a large number of false positives. This accuracy may be vital for neurologists to assess whether certain medication and treatment is effective, or even adversely affecting a patient, something that is difficult to do currently.

6.4 Website Analysis

All methods of data collection, feature extraction, and model querying via the web application were validated to be effective and successful when done in an automated manner. Data collection depended on

the user but usually took under 6 minutes. Pre-processing and Feature extraction usually took 4 minutes, and prediction via the model usually took 2 minutes. As such the goal of a rapid diagnosis with ParkinSense was achieved, with the entire diagnosis taking under 12 minutes, in sharp contrast to current industry methods that can take days to weeks. Therefore, ParkinSense suggests that an entirely contactless and accurate diagnosis via web-and-microphone-derived biomarkers is quite effective.

Additionally, users could track and compare their severity over time on both scales, via a Graphical User Interface (GUI) that involves graphs and plots. Examples of the GUI can be found in the Appendix.

Furthermore, since the target demographic of the website is quite different in age than those usually quite experienced in technology, especially computer and web applications, it is important to ensure that the target demographic is able to easily and accurately use the website. As part of the end-of-study survey, the web application was rated *4.8 out of 5* in terms of ease of use. Although this rating was from the data-collection site, the actual diagnosis site is nearly identical in layout and process.

No notable performance improvements was found when using offline batch retraining, although this was likely due to a small authentic sample size.

VII. CONCLUSION

7.1 Error Analysis

The largest source of error in correctly diagnosing a patient for PD is the EBR classifier. It had the least number of data points out of all the classifiers, and data had to be augmented for its use in the overall model. While this proved to be effective, it may have introduced certain biases or errors that may only be observable in large validation trials.

Additionally, for dataset aggregation in part 4.1, certain features likely were not collected in similar manners for each dataset, which may have introduced some noise that made the model underperform. Furthermore, during this aggregation, some features were discarded in favor of obtaining a larger dataset that was compatible with more child datasets. As a result, this may have discarded some features that had high predictive power in differentiating PD patients from HC. Furthermore, patients of different backgrounds and cultures may introduce bias that could lead to errors in the application.

Finally, some errors in the model may be a result of some of the training set patients being incorrectly diagnosed. Because of the high level of r , the model tends to be biased towards a positive PD diagnosis, which may result in an error, when the individual does not have PD and instead has a disorder that imitates a few symptoms of PD.

7.2 Future Work and Applications

One quite promising approach involves measuring saccades, or rapid eye movements[56]. Individuals with PD often have oculomotor abnormalities in regard to saccades that can be measured and analyzed [56]. While this approach may be difficult to implement with the typically low-quality webcams found on

most computers (relative to gaze-tracking headsets and technologies), [56], found saccade analysis to be an effective method of PD diagnosis when the video was recorded on a mobile phone. Saccade analysis may hold the key to unlocking another modality that can be tapped into for remote PD analysis.

Indeed, in this study, saccades were analyzed as a possible addition to the multimodal application. However, a suitable approach was not developed for use in ParkinSense. In the regard that future researchers may be able to build upon this line of methodology, the approach used by the researcher in this study will be described below.

Since saccades represent rapid eye movements, a test of some sort must be developed. For this study, a black ball moves across a white screen, alternating directions when it nears an edge. While little research has been conducted on this topic, a recent study proposes that single-eye horizontal saccades may be of significant interest [57]. In this case, when the ball changes direction, one eye deviates from the previous gaze of both eyes and follows the direction of the ball. On the other hand, the other eye will sometimes maintain the previous direction, slowing down in the direction that opposes the movement of the ball. This will result in tremors in a gaze that indicate poor motor control.

The difficulty in this approach is accurate gaze estimation. First, the user's face is landmarked and the pupil's extracted. Then the user is requested to look at all four corners of the screen in succession to calibrate the algorithm. From here the coordinate for the y direction can be easily calculated by calculating the Euler angles. For a specific gaze, z , and a set of calibration points $\{TL, TR, BL, BR\}$ indicating the coordinates of the pupil at the top left, top right, bottom left, and bottom right of the active area during calibration, a specific gaze estimation for y can be calculated as:

$$gaze_y = (z_y - TL_y) / (BL_y - TL_y) * SH + ST$$

Where SH represents the height of the active area which can be easily measured via the website and ST measures the distance from the top of the active area to the top of the screen. A similar method can be conducted for the x axis.

However, this method suffers from inaccuracy when the user's face is not aligned to the plane of the camera, and due to the low-quality resolution of most commercial laptop webcams.

Furthermore, the smooth pursuit can also be estimated from an application like ParkinSense. Smooth Pursuit aptly describes the movement of the eyes in a smooth motion, in contrast to saccades.

Both of these approaches can be added to the current diagnosis application, without significantly altering the number of steps for the diagnosis itself. As the participant reads the passage, the movement from across the line the movement of the eye can be generalized to smooth pursuit. On the other hand, as the participant jumps from one line to the next, and moves the eye quickly to the start of the next line, the behavior can be compared to that of a horizontal saccade, albeit with a slight vertical movement.

ParkinSense: Contactless Parkinson's Disease Diagnosis, Telemonitoring, and Severity Analysis via Multimodal Machine Learning and Digital Biomarkers

Furthermore, certain features, such as speech rate, blink duration, blink latency, reading rate, and head tremors that could be calculated from data collected in an environment similar to ParkinSense, also provide multiple other opportunities, that have had success in PD diagnosis in the past in a labs setting, and could be combined with ParkinSense for greater accuracy rates.

The researcher in this study aims to test this software, combined with other modalities, for longitudinal clinical tests on live patients in the near future to ensure the telemonitoring feature is functioning as expected. While it is expected that synthetic data is quite similar to live patient data, it is imperative to verify such metrics. In the meantime, I will release ParkinSense without the telemonitoring feature, pending approval from federal and state regulatory agencies.

ParkinSense at first included the ability to change languages, although this feature was removed, because individuals of different backgrounds using this application may result in a misdiagnosis. As a result, it may be vital to train the application on people from other regions or backgrounds, so that the application can successfully be broad-based to countries with substantially different cultures than the US.

Finally, other approaches to PD diagnosis, or other diseases with digital biomarkers, can benefit from a similar contactless diagnosis framework. By analyzing symptoms rapidly, accurately, and entirely contactlessly, many diagnosis tools can broad-base their technology to millions more individuals across the world, who do not readily have access to institutional or medical-facility instruments and technology.

7.3 Major Contributions

While a few papers have been able to accurately create scripts that can diagnose individuals with Parkinson's Disease, either from Vocal Symptoms, or Facial Symptoms, not much work in this vein has been done. Additionally, the vast, majority of papers that diagnose Parkinson's use invasive data, such as MRIs, gene sequencing, blood tests, and vocal data collected in a studio with a professional microphone.

As such, ParkinSense is

- I. This is the first time Vocal Symptoms and Facial Symptoms are combined for Parkinson's Disease diagnosis.
- II. The first time Eye Blink Rate is used as a symptom of Parkinson's Disease diagnosis.
- III. The first time a fully automated application is made from diagnosis and is available to the public. There exists no other application that can extract features from a recording and make a diagnosis and severity classification. ParkinSense is the first time anyone implement a solution for Parkinson's Disease diagnosis into something that can be used by anyone.
- IV. The first time users can track the severity of PD over time, to make educated assessments about the effectiveness of certain medications and treatments.
- V. The first time that severity classification and diagnosis is done with the same multimodal model.
- VI. The first time a website and mobile device application is developed for Parkinson's Disease diagnosis
- VII. One of the first times that a multimodal application is used for Parkinson's Diagnosis, and is the first time a multimodal application is used on digital biomarkers for Parkinson's Disease diagnosis.

ParkinSense: Contactless Parkinson's Disease Diagnosis, Telemonitoring, and Severity Analysis via Multimodal Machine Learning and Digital Biomarkers

- VIII. The first-time diagnosis and severity classification are combined into a single application for Parkinson's Diagnosis.
- IX. The first time synthetic data is used in this manner for Parkinson's Patients to increase accuracy.
- X. The first time that data augmentation techniques are used for Parkinson's Patients to increase accuracy, Over-current industry methods of diagnosis, ParkinSense is
 - 1. Cheaper: Current methods cost \$5,000+, while ParkinSense costs \$0
 - 2. Accurate: Current Methods misdiagnose 25-40% of people, while ParkinSense misdiagnoses 0.28% of people.
 - 3. Rapid: Current Methods of diagnosis take days to weeks, while ParkinSense takes 12 minutes.
 - 4. Remote: Current methods of diagnosis involve either a neurologist or invasive scans and injections, while ParkinSense can be used completely from the comfort of one's home using a laptop or phone.

7.4 Final Remarks

ParkinSense makes encouraging progress in the development of PD contactless diagnosis and severity analysis software via machine learning technologies and multiple modalities. ParkinSense automates data collection and feature extraction on the web application, and regarding the unimodal models, performed similarly to many top models. Furthermore, I introduce the first model that involves PD diagnosis classification through EBR. Additionally, I developed UPDMS and H&Y Scale predictors that perform quite well. ParkinSense integrates all of this together, to develop a PD diagnosis and severity analysis application, that outperforms most unimodal and multimodal diagnosis tools in literature for PD diagnosis and severity and progression metrics. All of this is accessible through a rapid and accurate web application. ParkinSense is the first of its type to offer such rapidness, and accuracy, for free, and entirely remotely. ParkinSense is also the first application to offer severity tracking and submission, which may prove to be vital when prescribing and using medications. ParkinSense juxtaposes current methods, which are quite invasive, requiring scans, injections, and hours of clinical diagnostic tests, and are also expensive, costing thousands of dollars. This makes it out of reach for billions of people, an issue ParkinSense aims to resolve. ParkinSense suggests that contactless PD diagnosis and severity tracking can be conducted accurately and rapidly, which may prove invaluable for those without access to PD diagnosis due to barriers, immobility, or associated costs. The significant accuracy of ParkinSense demonstrates the effectiveness of multimodal machine learning algorithms, data augmentation, and synthetic patient generation, and may allow millions worldwide to be diagnosed correctly, ensuring effective medication can be distributed immediately, preventing PD progression, as well as improving the quality of life for PD patients.

VIII. APPENDIX

Images of the DCS, DSAS and mobile application can be found below.

ParkinSense: Contactless Parkinson's Disease Diagnosis, Telemonitoring, and Severity Analysis via Multimodal Machine Learning and Digital Biomarkers




Fig 1. Preparation Page




Fig 1. Passage Task




Fig 1. Recording Overview



Fig 1. Login Page




Fig 2. Short Informed Consent (full informed consent can be viewed at bottom of screen)




Fig 3. Treatment and Medication Effectiveness



Fig 4. Signing Page



Fig 5. Dashboard



Fig 6. Treatment and Medication Effectiveness



Fig 7. Diagnosis Overview




Fig 8 Predicted Symptoms




Fig 9. Progression Estimation



Fig 10. Severity Graph

REFERENCES

Note: all images, graphs, and tables were designed and created by the researcher.

- [1] L. Shen, "Gut, oral and nasal microbiota and Parkinson's disease," *Microbial Cell Factories*, vol. 19, no. 1, 2020.
- [2] L. D. Zerden, T. Guan, J. Shurer, L. Kreitzer, and E. Book, "Social work, Parkinson's disease care, and covid-19," *Social Work in Health Care*, vol. 61, no. 3, pp. 139–157, 2022.
- [3] M. Öberg, I. Fabrik, D. Fabrikova, N. Zehetner, and A. Härtlova, "The role of innate immunity and inflammation in Parkinson's disease," *Scandinavian Journal of Immunology*, vol. 93, no. 5, 2021.
- [4] W. Dauer and S. Przedborski, "Parkinson's disease," *Neuron*, vol. 39, no. 6, pp. 889–909, 2003.
- [5] A. H. Rajput, "Frequency and cause of Parkinson's disease," *Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques*, vol. 19, no. S1, pp. 103–107, 1992.
- [6] M. Lew, "Overview of Parkinson's disease," *Pharmacotherapy*, vol. 27, no. 12 Part 2, 2007.
- [7] W. Poewe, K. Seppi, C. M. Tanner, G. M. Halliday, P. Brundin, J. Volkmann, A.-E. Schrag, and A. E. Lang, "Parkinson disease," *Nature Reviews Disease Primers*, vol. 3, no. 1, 2017.
- [8] M. Stacy, P. Hickey, and M. Stacy, "Available and emerging treatments for Parkinson's disease: A Review," *Drug Design, Development and Therapy*, vol. 2011, pp. 241–254, May 2011.
- [9] F. L. Pagan, "Improving outcomes through early diagnosis of Parkinson's disease," *The American Journal of Managed Care*, vol. 18, pp. 176–182, 2012.
- [10] M. Olson, T. E. Lockhart, and A. Lieberman, "Motor learning deficits in Parkinson's disease (PD) and their effect on training response in gait and balance: A narrative review," *Frontiers in Neurology*, vol. 10, 2019.
- [11] J. C. Greenland and R. A. Barker, "The differential diagnosis of Parkinson's disease," *Parkinson's Disease: Pathogenesis and Clinical Aspects*, pp. 109–128, 2018.
- [12] "The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations," *Movement Disorders*, vol. 18, no. 7, pp. 738–750, 2003.
- [13] J. Jankovic and A. Tarakad, "Faculty opinions recommendation of measuring Parkinson's disease over time: The real-world within-subject reliability of the MDS-UPDRS.," *Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature*, 2020.
- [14] E. Tolosa, G. Wenning, and W. Poewe, "The diagnosis of Parkinson's disease," *The Lancet Neurology*, vol. 5, no. 1, pp. 75–86, 2006.
- [15] W. H. Chen, T. J. Chiang, M. C. Hsu, and J. S. Liu, "The validity of eye blink rate in Chinese adults for the diagnosis of Parkinson's disease," *Clinical Neurology and Neurosurgery*, vol. 105, no. 2, pp. 90–92, Apr. 2003.
- [16] N. P. Quinn, "Parkinson's disease: clinical features," *Baillieres Clin Neurol.*, vol. 6, no. 1, pp. 1–13, 1997.
- [17] N. Fothergill-Misbah, R. Walker, J. Kwasa, J. Hooker, and K. Hampshire, "'Old people problems', uncertainty and legitimacy: Challenges with diagnosing Parkinson's disease in Kenya," *Social Science & Medicine*, vol. 282, p. 114148, Aug. 2021.
- [18] R. Pahwa and K. E. Lyons, "Early Diagnosis of Parkinson's Disease: Recommendations From Diagnostic Clinical Guidelines," *Implications of Early Treatment for Parkinson's Disease*, vol. 16, no. 4, Mar. 2010.
- [19] M. Tinelli, P. Kanavos, and F. Grimaccia, London School of Economics and Political Science, London, rep., Mar. 2016.
- [20] Parkinson's disease: National clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians, 2006.
- [21] S.-Y. Lim, A. H. Tan, A. Ahmad-Annuar, C. Klein, L. C. Tan, R. L. Rosales, R. Bhidayasiri, Y.-R. Wu, H.-F. Shang, A. H. Evans, P. K. Pal, N. Hattori, C. T. Tan, B. Jeon, E.-K. Tan, and A. E. Lang,

- "Parkinson's disease in the Western Pacific region," *The Lancet Neurology*, vol. 18, no. 9, pp. 865–879, 2019.
- [22] A. Channa, N. Popescu, and V. Ciobanu, "Wearable solutions for patients with Parkinson's disease and Neurocognitive Disorder: A systematic review," *Sensors*, vol. 20, no. 9, p. 2713, 2020.
 - [23] B. Heim, F. Krismer, R. De Marzi, and K. Seppi, "Magnetic resonance imaging for the diagnosis of Parkinson's disease," *Journal of Neural Transmission*, vol. 124, no. 8, pp. 915–964, 2017.
 - [24] F. Amato, L. Borzì, G. Olmo, and J. R. Orozco-Arroyave, "An algorithm for Parkinson's disease speech classification based on isolated words analysis," *Health Information Science and Systems*, vol. 9, no. 1, 2021.
 - [25] S. Chakraborty, S. Aich, and H.-C. Kim, "Detection of Parkinson's disease from 3T T1 weighted MRI scans using 3D convolutional neural network," *Diagnostics*, vol. 10, no. 6, p. 402, 2020.
 - [26] Y. Uehara, S.-I. Ueno, H. Amano-Takeshige, S. Suzuki, Y. Imamichi, M. Fujimaki, N. Ota, T. Murase, T. Inoue, S. Saiki, and N. Hattori, "Non-invasive diagnostic tool for Parkinson's disease by sebum RNA profile with machine learning," *Scientific Reports*, vol. 11, no. 1, 2021.
 - [27] K. Tjaden, "Speech and swallowing in Parkinson's disease," *Topics in Geriatric Rehabilitation*, vol. 24, no. 2, pp. 115–126, 2008.
 - [28] S. Pinto, R. Cardoso, J. Sadat, I. Guimarães, C. Mercier, H. Santos, C. Atkinson-Clement, J. Carvalho, P. Welby, P. Oliveira, M. D'Imperio, S. Frota, A. Letanneux, M. Vigario, M. Cruz, I. P. Martins, F. Viallet, and J. J. Ferreira, "Dysarthria in individuals with Parkinson's disease: A protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (fralusopark)," *BMJ Open*, vol. 6, no. 11, 2016.
 - [29] H. Hazan, D. Hilu, L. Manevitz, L. O. Ramig, and S. Sapir, "Early diagnosis of Parkinson's disease via machine learning on speech data," *2012 IEEE 27th Convention of Electrical and Electronics Engineers in Israel*, 2012.z
 - [30] J. S. Almeida, P. P. Rebouças Filho, T. Carneiro, W. Wei, R. Damaševičius, R. Maskeliūnas, and V. H. de Albuquerque, "Detecting Parkinson's disease with sustained phonation and speech signals using Machine Learning Techniques," *Pattern Recognition Letters*, vol. 125, pp. 55–62, 2019.
 - [31] W. E. Rinn, "The neuropsychology of Facial Expression: A review of the neurological and psychological mechanisms for producing facial expressions.,," *Psychological Bulletin*, vol. 95, no. 1, pp. 52–77, 1984.
 - [32] P. Ekman and W. V. Friesen, "Facial action coding system," *PsycTESTS Dataset*, 1978.
 - [33] M. R. Ali, T. Myers, E. Wagner, H. Ratnu, E. R. Dorsey, and E. Hoque, "Facial expressions can detect Parkinson's disease: Preliminary evidence from videos collected online," *npj Digital Medicine*, vol. 4, no. 1, 2021.
 - [34] C. N. Karson, P. A. Lewitt, D. B. Calne, and R. J. Wyatt, "Blink rates in parkinsonism," *Annals of Neurology*, vol. 12, no. 6, pp. 580–583, 1982.
 - [35] E. Fitzpatrick, N. Hohl, P. Silburn, C. O'Gorman, and S. A. Broadley, "Case-control study of blink rate in Parkinson's disease under different conditions," *Journal of Neurology*, vol. 259, no. 4, pp. 739–744, 2011.
 - [36] Syed, Nadir A; Ali, Farwa; Sher, Khalid; Ikram, Amer; Soomro, Bashir; Shahbaz, Naila; Sheeran, Mughis; Jamil, Sarwar; Numan, Ahsan; Lakhair, Manzoor; Awan, Irshad; Baruch, Saleem; and Basheer, Haroon (2015) "National guidelines for diagnosis and management of Parkinson's disease in Pakistan," *Pakistan Journal of Neurological Sciences (PJNS)*: Vol. 10: Iss. 1, Article 14.
 - [37] A. M. Sidahmed and H. A. Ali, "Frequency and associated factors of autonomic dysfunction in patients with Parkinson's disease in Khartoum State," *Advances in Parkinson's Disease*, vol. 08, no. 04, pp. 63–74, 2019.
 - [38] J. C. Vasquez-Correa, T. Arias-Vergara, J. R. Orozco-Arroyave, B. Escoffier, J. Klucken, and E. Noth, "Multimodal assessment of Parkinson's disease: A deep learning approach," *IEEE Journal of Biomedical and Health Informatics*, vol. 23, no. 4, pp. 1618–1630, 2019.

ParkinSense: Contactless Parkinson's Disease Diagnosis, Telemonitoring, and Severity Analysis via Multimodal Machine Learning and Digital Biomarkers

- [39] G. Battineni, M. A. Hossain, N. Chintalapudi, E. Traini, V. R. Dhulipalla, M. Ramasamy, and F. Amenta, "Improved Alzheimer's disease detection by MRI using multimodal machine learning algorithms," *Diagnostics*, vol. 11, no. 11, p. 2103, 2021.
- [40] R. Bhidayasiri and D. Tarsy, "Parkinson's disease: Hoehn and Yahr Scale," *Current Clinical Neurology*, pp. 4–5, 2012.
- [41] C. Kotsavasiloglou, N. Kostikis, D. Hristu-Varsakelis, and M. Arnaoutoglou, "Machine learning-based classification of simple drawing movements in Parkinson's disease," *Biomedical Signal Processing and Control*, vol. 31, pp. 174–180, 2017.
- [42] Naranjo, L., PÃ©rez, C.J., Campos-Roca, Y., MartÃ±, J.: Addressing voice recording replications for Parkinson's disease detection. *Expert Systems With Applications* 46, 286-292 (2016)
- [43] Erdogdu Sakar, B., Isenkul, M., Sakar, C.O., Sertbas, A., Gurgen, F., Dell, S., Apaydin, H., Kursun, O., 'Collection and Analysis of a Parkinson Speech Dataset with Multiple Types of Sound Recordings, *IEEE Journal of Biomedical and Health Informatics*, vol. 17(4), pp. 828- 834, 2013.
- [44] Athanasios Tsanas, Max A. Little, Patrick E. McSharry, Lorraine O. Raming (2009), 'Accurate telemonitoring of Parkinson's disease progression by non-invasive speech tests', *IEEE Transactions on Biomedical Engineering*.
- [45] Sakar, C.O., Serbes, G., Gunduz, A., Tunc, H.C., Nizam, H., Sakar, B.E., Tutuncu, M., Aydin, T., Isenkul, M.E. and Apaydin, H., 2018. A comparative analysis of speech signal processing algorithms for Parkinson's disease classification and the use of the tunable Q-factor wavelet transform. *Applied Soft Computing*,
- [46] 'Exploiting Nonlinear Recurrence and Fractal Scaling Properties for Voice Disorder Detection', Little MA, McSharry PE, Roberts SJ, Costello DAE, Moroz IM. *BioMedical Engineering OnLine* 2007, 6:23 (26 June 2007)
- [47] A. Torfi and E. A. Fox, "Corgan: Correlation-capturing convolutional generative adversarial networks for generating Synthetic Healthcare Records," arXiv.org, 04-Mar-2020. [Online]. Available: <https://arxiv.org/abs/2001.09346>.
- [48] F. Eyben, M. Wöllmer, and B. Schuller, "Opensmile," Proceedings of the international conference on Multimedia - MM '10, 2010.
- [49] S. I. Serengil and A. Ozpinar, "Hyperextended Lightface: A facial attribute analysis framework," 2021 International Conference on Engineering and Emerging Technologies (ICEET), 2021.
- [50] T. Baltrusaitis, A. Zadeh, Y. C. Lim, and L.-P. Morency, "OpenFace 2.0: Facial Behavior Analysis Toolkit," 2018 13th IEEE International Conference on Automatic Face & Gesture Recognition (FG 2018), 2018.
- [51] J. Robert, PyDub. PyDub, 2014.
- [52] K. Cortacero, T. Fischer, and Y. Demiris, "RT-BENE: A dataset and baselines for real-time Blink estimation in Natural Environments," 2019 IEEE/CVF International Conference on Computer Vision Workshop (ICCVW), 2019.
- [53] A. Goncalves, P. Ray, B. Soper, J. Stevens, L. Coyle, and A. P. Sales, "Generation and evaluation of Synthetic Patient Data," *BMC Medical Research Methodology*, vol. 20, no. 1, 2020.
- [54] J. Mei, C. Desrosiers, and J. Frasnelli, "Machine learning for the diagnosis of Parkinson's disease: A review of literature," *Frontiers in Aging Neuroscience*, vol. 13, 2021.
- [55] M.Nilashi,R.A.Abulmallooh,B.Minaei-Bidgoli, S.Samad, M.Yousuf Ismail, A. Alhargan, and W. Abdu Zogaan, "Predicting Parkinson's disease progression: Evaluation of ensemble methods in machine learning," *Journal of Healthcare Engineering*, vol. 2022, pp. 1–17, 2022.
- [56] Z. Chang, Z. Chen, C. D. Stephen, J. D. Schmahmann, H.-T. Wu, G. Sapiro, and A. S. Gupta, "Accurate detection of cerebellar smooth pursuit eye movement abnormalities via mobile phone video and Machine Learning," *Scientific Reports*, vol. 10, no. 1, 2020.
- [57] Pretegiani E, Optican LM. Eye Movements in Parkinson's Disease and Inherited Parkinsonian Syndromes. *Front Neurol*. 2017 Nov 9;8:592. doi: 10.3389/fneur.2017.00592. PMID: 29170650; PMCID: PMC5684125.